Kamada To Produce GLASSIA For Shire Through 2020 - Quick Facts

(RTTNews) - Kamada Ltd. (KMDA) announced the extension of the strategic partnership with Shire plc (SHP.L, SHPG) for GLASSIA. Kamada will continue to produce GLASSIA through 2020 for Shire, after which Shire may produce the product at their facility and pay Kamada established royalty rates. Minimum revenue for GLASSIA in the extended agreement for the years 2017 to 2020 will reach approximately $237 million and may be expanded to $288 million during that period.

GLASSIA is the first available ready-to-infuse liquid alpha1-proteinase inhibitor and is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency. GLASSIA is approved by the FDA and is marketed through a strategic partnership with Baxalta in the US.